Markets:

Overview

News

Currencies

International

Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.600 -0.080 (-1.71%)

Streaming Delayed Price Updated: 9:34 AM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stocks That Hit 52-Week Lows On Tuesday ↗

August 30, 2022

On Tuesday, 250 stocks hit new 52-week lows.

Via Benzinga

SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders ↗

August 12, 2022

Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan

Via Benzinga

SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome ↗

June 29, 2022

TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd.

Via Benzinga

SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder ↗

June 23, 2022

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment

Via Benzinga

Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration ↗

August 25, 2022

SciSparc Ltd. (NASDAQ: SPRC) recently announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel...

Via Benzinga

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc. ↗

August 25, 2022

Results indicate significant decrease in cocaine craving in a sub-group that received the treatment

Via Benzinga

Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday ↗

August 25, 2022

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.

Via Benzinga

SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins ↗

June 15, 2022

JV Targets Potential Drugs for Cancers and Infectious Diseases

Via Benzinga

Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know ↗

August 24, 2022

Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd.

Via Benzinga

Why Are Psychedelics Stocks Up Today? ↗

August 24, 2022

Shares of SEEL stock are in the green after the company received a grant from the Michael J. Fox Foundation to advance its SLS-004 candidate.

Via InvestorPlace

S&P 500 Edges Higher; Nordstrom Shares Plummet ↗

August 24, 2022

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Wednesday.

Via Benzinga

Dow Rises Over 100 Points; US Crude Oil Inventories Decline Higher Than Expected ↗

August 24, 2022

U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.

Via Benzinga

Why SciSparc Stock Is Skyrocketing Today ↗

August 24, 2022

SciSparc Ltd (NASDAQ: SPRC) shares are soaring Wednesday after the company announced additional pre-clinical results of its psychedelic-based pharma collaboration for treatment of cocaine addiction...

Via Benzinga

Why Citi Trends Is Trading Lower By 17%, Here Are 47 Stocks Moving In Wednesday's Mid-Day Session ↗

August 24, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 77% to $2.35. Bright Minds priced overnight marketed offering of 2.858 million units at $1.40 per unit.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

August 17, 2022

We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning!

Via InvestorPlace

Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket ↗

August 17, 2022

Gainers Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share.

Via Benzinga

This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday ↗

August 16, 2022

Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

August 15, 2022

On Monday, 31 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

August 12, 2022

On Friday, 39 companies reached new 52-week lows.

Via Benzinga

These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches ↗

July 20, 2022

More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

July 28, 2022

On Thursday, 108 companies set new 52-week lows.

Via Benzinga

SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome ↗

July 08, 2022

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of...

Via Benzinga

SciSparc Announces Buyback Equal To 12% Of Float ↗

July 07, 2022

SciSparc Ltd. (NASDAQ: SPRC) recently announced that its board of directors authorized the company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par...

Via Benzinga

Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.

July 07, 2022

NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a...

From Traders News Source

Via AccessWire

SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome ↗

June 30, 2022

SciSparc Ltd. (NASDAQ: SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study...

Via Benzinga

SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome ↗

June 29, 2022

SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed...

Via Benzinga

R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

June 29, 2022

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...

Via FinancialNewsMedia

SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray ↗

June 28, 2022

The opioid crisis has raised public awareness about the dire state of pain-management options for the estimated 50 million Americans with chronic pain.

Via Benzinga

SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment ↗

June 24, 2022

SciSparc Ltd.

Via Benzinga

93 Biggest Movers From Yesterday ↗

June 14, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.